Relapses Requiring Intravenous Steroid Use and Multiple-Sclerosis-related Hospitalizations : Integrated Analysis of the Delayed-release Dimethyl Fumarate Phase III Studies
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F15%3A10313208" target="_blank" >RIV/00216208:11110/15:10313208 - isvavai.cz</a>
Alternative codes found
RIV/00064165:_____/15:10313208
Result on the web
<a href="http://dx.doi.org/10.1016/j.clinthera.2015.09.011" target="_blank" >http://dx.doi.org/10.1016/j.clinthera.2015.09.011</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1016/j.clinthera.2015.09.011" target="_blank" >10.1016/j.clinthera.2015.09.011</a>
Alternative languages
Result language
angličtina
Original language name
Relapses Requiring Intravenous Steroid Use and Multiple-Sclerosis-related Hospitalizations : Integrated Analysis of the Delayed-release Dimethyl Fumarate Phase III Studies
Original language description
Purpose The purpose was to report the effects of delayed-release dimethyl fumarate (DMF; also known as gastro-resistant DMF) on the number of relapses requiring intravenous (IV) steroids and multiple sclerosis (MS)-related hospitalizations using integrated data from the Phase III DEFINE and CONFIRM studies. Data DEFINE and CONFIRM were pooled and analyzed using a negative binomial regression model (adjusted for study and region). Data obtained after subjects switched to an alternative MS therapy were not included in the analysis. Only relapses confirmed by the Independent Neurology Evaluation Committee were included in the analysis of relapses requiring IV steroids. Findings The study population (intention-to-treat) comprised 2301 patients who receivedeither placebo (n = 771), DMF BID (n = 769), or DMF TID (n = 761). Baseline demographic and disease characteristics were generally well balanced among treatment groups. Throughout the 2-year studies, the total number of relapses treated
Czech name
—
Czech description
—
Classification
Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FH - Neurology, neuro-surgery, nuero-sciences
OECD FORD branch
—
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2015
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Clinical Therapeutics
ISSN
0149-2918
e-ISSN
—
Volume of the periodical
37
Issue of the periodical within the volume
11
Country of publishing house
US - UNITED STATES
Number of pages
9
Pages from-to
2543-2551
UT code for WoS article
000366242900017
EID of the result in the Scopus database
2-s2.0-84947942315